Diabetes Care, Vol 16, Issue 8 1137-1145, Copyright © 1993 by American Diabetes Association

ARTICLES

Hemostasis variables in type I diabetic patients without demonstrable vascular complications

C el Khawand, J Jamart, J Donckier, B Chatelain, E Lavenne, M Moriau and M Buysschaert
Department of Endocrinology and General Internal Medicine, University Clinics of Mont-Godinne (Universite Catholique de Louvain), Yvoir, Belgium.

OBJECTIVE--To determine hemostasis variables in type I diabetic patients without clinically demonstrable micro- and macroangiopathy and to relate them to glycemic control. RESEARCH DESIGN AND METHODS--Fifty patients and 50 comparable control subjects were enrolled in this study. The patients were subdivided in two groups, according to their level of HbA1c (group 1, n = 30, HbA1c < or = 8%; group 2, n = 20, HbA1c > 8%). We determined the platelet count, the platelet aggregation in the spontaneous state and in the presence of ADP or collagen, beta-thromboglobulin, platelet factor 4, fibrinogen, von Willebrand factor (factors VIII:C, VIIIR:Ag, and VIIIR:VW), plasma and urinary fibrinopeptide A, euglobulin lysis time, anticoagulant proteins C and S, and plasma viscosity. RESULTS--All coagulation variables were significantly higher in diabetic patients compared with control subjects. Moreover, when the patients were subdivided according to their levels of HbA1c, the hemostatic disturbances appeared significantly more pronounced in the poorly controlled than in the well-controlled subjects. CONCLUSIONS--This study confirms the existence of a state of hypercoagulability in type I diabetes. This hypercoagulability may be related to poor glycemic control. Our study suggests that the hemostasis disturbances precede demonstrable vascular complications.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I A Adediran, R T Ikem, and M F Borisade Fibrinolytic activity in Nigerian diabetics Postgrad. Med. J., October 1, 2004; 80(948): 610 - 612. [Abstract] [Full Text] [PDF]

				R. L. Klein, S. J. Hunter, A. J. Jenkins, D. Zheng, A. J. Semler, J. Clore, W. T. Garvey, and The DCCT/EDIC Study Group Fibrinogen Is a Marker for Nephropathy and Peripheral Vascular Disease in Type 1 Diabetes: Studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort Diabetes Care, May 1, 2003; 26(5): 1439 - 1448. [Abstract] [Full Text] [PDF]

				I. L Williams, A. Vazir, and A. G Zaman Review: The management of stable angina in diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 18 - 25. [Abstract] [PDF]

				J. J. Stec, H. Silbershatz, G. H. Tofler, T. H. Matheney, P. Sutherland, I. Lipinska, J. M. Massaro, P. F.W. Wilson, J. E. Muller, and R. B. D'Agostino Sr Association of Fibrinogen With Cardiovascular Risk Factors and Cardiovascular Disease in the Framingham Offspring Population Circulation, October 3, 2000; 102(14): 1634 - 1638. [Abstract] [Full Text] [PDF]

				M. Shechter, C. N. Bairey Merz, M. J. Paul-Labrador, and S. Kaul Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease J. Am. Coll. Cardiol., February 1, 2000; 35(2): 300 - 307. [Abstract] [Full Text] [PDF]

				T. Nagao, M. Hamamoto, A. Kanda, T. Tsuganesawa, M. Ueda, K. Kobayashi, T. Miyazaki, and A. Terashi Platelet Activation Is Not Involved in Acceleration of the Coagulation System in Acute Cardioembolic Stroke With Nonvalvular Atrial Fibrillation Stroke, August 1, 1995; 26(8): 1365 - 1368. [Abstract] [Full Text]